Novo Nordisk has appointed Maziar Mike Doustdar, a long-standing executive within the company, as its new CEO. The decision comes amid efforts to navigate recent market challenges and strengthen the company’s position in the competitive pharmaceutical industry.
Doustdar, who has held key leadership roles at Novo Nordisk for several years, is expected to leverage his deep understanding of the company’s operations and strategic vision to drive growth and innovation.
In a statement, the company highlighted that Doustdar’s appointment reflects its commitment to stability and continuity during a period marked by shifting market dynamics and increased competition.
“Mike brings invaluable experience and insight,” said the Novo Nordisk board chair. “His leadership will be critical as we address current challenges and capitalize on new opportunities in global healthcare.”
Doustdar succeeds the outgoing CEO as Novo Nordisk aims to maintain its leadership in diabetes care and expand its footprint in other therapeutic areas.
